CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo&#

CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

South San Francisco , California , United States , Norway , Castres , Midi Pyrées , France , Iceland , United Kingdom , Liechtenstein , French , Pierre Fabre , Eric Hyllengren , Alex Chapman , Eric Ducournau , Sylvain Choquet , Laure Sgandurra , Pascal Touchon , Atara Biotherapeutics Inc , Linkedin , Twitter , European Commission , Drug Administration , European Commission Approval , Nasdaq , Exchange Commission , European Union , European Medicines Agency , Securities Exchange , Health Care , Healthcare Products Regulatory Agency , Committee For Medicinal Products Human Use , Pierre Fabre Foundation , Wall Street , First Ever Allogeneict Cell Therapy , Opinion Based , Pivotal Phase , Favorable Risk Benefit , Commission Approval Expected , Medicinal Products , Human Use , Clinical Hematology Department , Authorization Application , Reliance Procedure , Breakthrough Therapy Designation , Pierre Fabre Oncology , Pierre Fabre Dermatology , Pierre Fabre Oral , South San , Securities Act , Securities Exchange Act , Southern California , Financial Condition ,